Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00252044
Status:
UNKNOWN
Last Update Posted:
2005-11-21
First Post:
2005-11-09
Brief Title:
Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
Sponsor:
Bronx VA Medical Center
Organization:
Bronx VA Medical Center
Study Overview
Official Title:
The Dopaminergic System in Schizotypal Personality Disorder Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
Status:
UNKNOWN
Status Verified Date:
2005-11
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hypothesis Schizotypal personality disorder patients will show cognitive improvements in 1 working memory 2 learning and memory 3 sustained attention 4 enhanced performance on the AX-CPT N-back and Eriksen during pergolide treatment There will be a significant diagnosis by drug administration of 03 mg of oral pergolide interaction for performance on the cognitive tasks with the schizotypal personality disorder group demonstrating significantly improved peformance compared to the other personality disorder group after pergolide compared with placebo
Design Randomized double-blind crossover study of pergolide vs placebo Half of subjects receive pergolide for eight weeks half of subjects receive placebo for four weeks followed by pergolide for four weeks
Design Randomized double-blind crossover study of pergolide vs placebo Half of subjects receive pergolide for eight weeks half of subjects receive placebo for four weeks followed by pergolide for four weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None